Changing from Cyclosporine to Tacrolimus as Salvage Therapy for Chronic Graft-Versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 6, 2000, Pages 613-620

  Carnevale Schianca, Fabrizio ^a   Martin, Paul ^a,b   Sullivan, Keith ^a,b   Flowers, Mary ^a,b   Gooley, Ted ^a,c   Anasetti, Claudio ^a,b   Deeg, Joachim ^a,b   Furlong, Terry ^a   McSweeney, Peter ^a,b   Storb, Rainer ^a,b   Nash, Richard A ^a,b,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic bone marrow transplantation; Chronic graft versus host disease; Corticosteroids; Refractory chronic graft versus host disease; Salvage therapy; Tacrolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SALVAGE THERAPY; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0033657112     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70026-7     Document Type: Article

References (46)

1. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Black-well Science; 1999:515-536.
2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14-21.
3. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S, eds. Graft-versus-Host Disease. 2nd ed. rev. & expd. New York: Marcel Dekker; 1997:525.
4. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998; 91:3637-3645.
5. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98:461-466.
6. Wagner JL, Flowers MED, Longton G, Storb R, Schubert M, Sullivan KM. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transplant. 1998;22:139-146.
7. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Thomas ED, Forman SJ, Blume KG, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999;12-18.
8. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood. 1988;72:555-561.
9. Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc. 1999;31:2203-2205.
10. Klintmalm GB, Goldstein R, Gonwa T, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation: US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993;25:679-688.
11. Mayer AD. Four-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc. 1999;31:27S-28S.
12. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60:580-584.
13. Starzl TE, Donner A, Eliasziw M, et al. Randomised trialomania? The multicentre liver transplant trials of tacrolimus [review]. Lancet. 1995;346:1346-1350.
14. Morris RE, Brown BW Jr. Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations. Lancet. 1995; 346:1310-1311.
15. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:423-428.
16. Mayer AD, Dmitrewski J, Squifflet J-P, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1996;64:436-443.
17. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation. 1991;52:590-594.
18. Storb R, Raff RF, Appelbaum FR, et al. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation. 1993;56:800-807.
19. Yu C, Storb R, Deeg HJ, et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplant. 1996;17:649-653.
20. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634-3641.
21. Fay JW, Wingard JR, Antin JH, et al. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood. 1996;87:3514-3519.
22. Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88:4383-4389.
23. Nash RA, Antin JH, Karanes C, et al. A phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068.
24. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-2314.
25. Hiraoka A. Results of a phase III study on prophylactic use of FK506 for acute GVHD compared with cyclosporin in allogeneic bone marrow transplantation [abstract]. Blood. 1997;90(suppl 1):561a. Abstract 2500.
26. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977; 49:511-533.
27. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
28. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
29. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators [review]. Stat Med. 1999;18:695-706.
30. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991;23:3225-3227.
31. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants: Japanese FK506 BMT Study Group. Bone Marrow Transplant. 1995;15:885-889.
32. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med. 1992;326:1055-1058.
33. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86: 3604-3609.
34. Koc S, Leisenring W, Flowers ME, Sullivan KM, Martin PJ. Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients [abstract]. Blood. 1999; 94(suppl 1):158a. Abstract 693.
35. Nash RA, Furlong T, Storb R, et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis [abstract]. Blood. 1997;90(suppl 1):105a. Abstract 459.
36. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61-65.
37. Redei I, Langston AA, Cherry JK, Allen A, Waller EK. Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GvHD [abstract]. Blood. 1999;94(suppl 1):159a. Abstract 698.
38. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-520.
39. Wingard JR, Nash RA, Przepiorka D, et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant. 1998;4:157-163.
40. Woo M, Przepiorka D, Ippoliti C, et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation [review]. Bone Marrow Transplant. 1997;20:1095-1098.
41. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant. 1999;5:94-97.
42. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97:865-870.
43. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990;89:733-738.
44. Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. 1998;22:67-71.
45. Stern JM, Chesnut CH III, Bruemmer B, et al. Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant. 1996;17:395-400.
46. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.